key: cord-0982137-0w00wjbh authors: Chahla, R. E.; Tomas-Grau, R. H.; Cazorla, S. I.; Ploper, D.; Vera Pingitore, E.; Aguilar Lopez, M.; Aznar, P.; Alcorta, M. E.; Velez, E. M. d. M.; Stagnetto, A.; Avila, C. L.; Maldonado Galdeano, C.; Socias, S. B.; Heinze, D.; Navarro, S. A.; Llapur, C.; Costas, D.; Flores, I.; Apfelbaum, G.; Mostoslavsky, R.; Mostoslavsky, G.; Perdigon, G. d. V.; Chehin, R. title: Past SARS-CoV-2 infection elicits a strong immune response after a single vaccine dose date: 2021-03-24 journal: nan DOI: 10.1101/2021.03.14.21253039 sha: a5d5fd88a50b8b7eefa4216e2016193cc1b7af24 doc_id: 982137 cord_uid: 0w00wjbh We hypothesized that in individuals with previous SARS-CoV-2 infection, the first vaccine dose would work as a booster, eliciting a faster and more intense immune response. We herein describe antibody responses to the first and second doses of Gam-COVID-Vac (SPUTNIK V) vaccine in health personnel of Tucuman, Argentina, with previous COVID-19 and compared it with uninfected personnel. Individuals with anti-SARS-CoV-2 titers at baseline showed significantly higher responses to the first dose than people with no prior history of disease (p <0.0001), with titers higher to those registered after the second dose in the control group, representing a clear secondary antibody response. This suggests that a single dose of SPUTNIK V for people with previous SARS-CoV-2 infection could contribute to a better use of available doses. We hypothesized that in individuals with previous SARS-CoV-2 infection, the first vaccine dose would work as a booster, eliciting a faster and more intense immune response. We herein describe antibody responses to the first and second doses of Gam-COVID-Vac (SPUTNIK V) vaccine in health personnel of Tucumán, Argentina, with previous COVID-19 5 and compared it with uninfected personnel. Individuals with anti-SARS-CoV-2 titers at baseline showed significantly higher responses to the first dose than people with no prior history of disease (p <0.0001), with titers higher to those registered after the second dose in the control group, representing a clear secondary antibody response. This suggests that a single dose of SPUTNIK V for people with previous SARS-CoV-2 infection could contribute to a better use of 10 available doses. The need to control the transmissibility and mortality associated with SARS-CoV-2 has transformed vaccines into a critical resource to mitigate the devastating effects of the pandemic 15 originated in Wuham in December 2019 (1, 2). The appearance of new virus variants (3), whose selective pressure depends on the transmission of the virus, reinforces the need to accelerate the vaccination process in all countries (4) . However, despite the unprecedented speed of development of different vaccines around the world, their availability remains very limited. This situation is even more critical in underdeveloped or developing countries. In Argentina, the local 20 regulatory authority has so far approved two adenovirus-based vaccines, Gam-COVID-Vac (SPUTNIK V) and Oxford-AstraZeneca, which rely on a prime-booster approach. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 24, 2021. ; https://doi.org/10.1101/2021.03.14.21253039 doi: medRxiv preprint The persistence of humoral and cellular immunity against SARS-CoV-2 in convalescent patients has generated new questions regarding the requirement for a two-dose regimen in both adenovirus-based and mRNA vaccines (5-7). In this context, this work aimed at studying the post-vaccination humoral immune response to SPUTNIK V in a population of individuals with previous SARS-CoV-2 seroconversion and comparing it with a control group with no previous for the purpose of this study. After vaccination with SPUTNIK V, anti-RBD antibody titers were measured at i) 0 days post vaccination (dpv), ii) 14 dpv and iii) 28 dpv (7 days after the second dose), in 252, 520 and 374 samples respectively. At the beginning of the vaccination scheme (0 dpv), the mean IgG anti-RBD titer was 210. After the first dose of SPUTNIK V (14 dpv), the All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 24, 2021. ; https://doi.org/10.1101/2021.03.14.21253039 doi: medRxiv preprint mean titer reached 753, while at 28 dpv, the mean titer rose to 1771, with 97.05% of individuals showing seropositivity (Fig. 1B) . A small but statistically significant difference was observed between antibody titers elicited 28 dpv between male and female HCP (Fig. 1C ). When subjects were grouped according to age (between 21-60 years of age), no statistical difference was found between mean antibody titers elicited by each age group (Fig. 1D ). dpv (dark grey squares) and 28 dpv (light grey triangles). *** p<0.0001. Statistical analysis was All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In order to perform a longitudinal case control study, we followed a group of 214 individuals and analyzed antibody titers measured at 0 dpv and 14 dpv ( Fig. 2A) . Of these, 107 completed the vaccination scheme with the second dose (Fig. 2B ). The first dose of SPUTNIK V (14 dpv), significantly increased antibody titers both in the group with pre-existing SARS-CoV-2 10 immunity (basal IgG anti-RBD +) (p<0.0001), as well as in those without detectable titers at baseline (p<0.0001) ( Fig. 2A) . However, the group that was seropositive at baseline achieved a much higher mean antibody titer at 14 dpv (5.4 fold higher) than the control group (p<0.0001). This highly significant difference suggests that a single dose vaccination in previously exposed individuals elicits a secondary-like immune response, acting essentially as an immune boost. 15 Even in individuals who underwent asymptomatic SARS-CoV-2 infection with basal anti-RBD IgG titers, their antibody response was substantially higher at 14 dpv than those with no basal antibodies (5.5 fold higher, p<0.0001) (Fig. S1 ). This asymptomatic group even registered a small but consistently higher mean antibody titer before being vaccinated (0 dpv) compared to the control group after receiving the first dose (14 dpv) (p<0.0001) (Fig. S1) . 20 In the subgroup that completed the full vaccination scheme (28 dpv), the second dose of SPUTNIK V elicited higher antibody titers in the group with pre-existing SARS-CoV-2 immunity (2302), compared to the control group (1297) (p <0.05) (Fig. 2B) . Notably, a single dose elicited higher antibody titers (14 dpv, 1450) in the seropositive group than two doses of the All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 24, 2021. ; https://doi.org/10.1101/2021.03.14.21253039 doi: medRxiv preprint vaccine in the seronegative group (28 dpv, 1297) (p<0.005) (Fig 2B) . Although this difference was statistically significant, the overall distribution of titers within the seropositive subgroup at 14 dpv appeared asymmetric, with the median significantly below the mean, indicative of a highly heterogeneous response to the vaccine (Fig. 2B) . Indeed, if this group is further separated based on titers below or above 400, then the response to the first dose becomes strongly 5 homogeneous in >400 subgroup (Fig 2C) , strongly suggesting that the anti-RBD IgG titers at baseline have a direct consequence in the overall response to the vaccine. Significant differences in anti-RBD titers were detected after each vaccine dose in both groups, underscoring the general effectiveness of the SPUTNIK V (10). With the aim of determining if there is an optimal window post-SARS-CoV-2 diagnosis in which 10 the SPUTNIK V vaccine stimulates higher antibody titers in seroconverted individuals, we analyzed the effect of days past between diagnosis (in individuals with confirmed positive RT-PCR) and vaccination (days post diagnosis, dpd) on anti-RBD IgG titers. Notably, there was no significant difference associated between dpd (at least up to 120 days) and antibody responses to the vaccine (Fig. 3A-C) . 15 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 24, 2021. ; https://doi.org/10.1101/2021.03.14.21253039 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 24, 2021. ; https://doi.org/10.1101/2021.03.14.21253039 doi: medRxiv preprint each group are indicated as a red line or a blue line, respectively. *** p<0.0001 ** p<0.005, *p<0.05. Statistics analysis was performed with Kolmogorov-Smirnov test. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 24, 2021. ; https://doi.org/10.1101/2021.03.14.21253039 doi: medRxiv preprint dpv) and second (28 dpv) vaccine doses when administered less than 90, between 90-120, and more than 120 days post diagnosis (dpd) of SARS-CoV-2 infection (by RT-PCR or antigen test) ns=not-significant. Statistical analyses were done with Dunn´s multiple comparison test (B-C) Correlation between the dpd and IgG anti-RBD titers generated by the first (B) (r=0.01245, p=0.8770) or second dose (C) of the SPUTNIK V vaccine (r=-0.03879, p=0.7045). The 5 correlation was analyzed using Pearson Correlation Coefficient. In a context of limited access to SARS-CoV-2 vaccines, our findings show that in individuals previously exposed to the virus, the first dose of SPUTNIK V elicits a strong humoral immune response comparable or even higher than that reached after two doses in individuals without 10 previous exposure to the virus. Our results suggest that the first dose seems to act as a booster for individuals with detectable anti-SARS-CoV-2 antibody titers (regardless if they were asymptomatic or not), and that screening for SARS-CoV-2 seropositive individuals with titers above 400 among the general population could serve to identify those who might require only one vaccination dose. A pneumonia outbreak associated with a new coronavirus of probable bat origin Understanding COVID-19 vaccine efficacy Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19 Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence We thank Mr. Claude Burgio (SkyBio LLC), Ing. Luis Rocha, Ing. Marina Gandur, Dr. Christian Jaroszewski, Dr. María de los Angeles Peral de Bruno and Lic. Lorena Naidicz. We thank Aaron Schmidt for providing valuable reagents. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Authors declare no competing interests.